HCA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $426.69
Market Cap (MRQ) $93.00B
P/E (TTM) 14.3
EPS (TTM) $29.82
Revenue (TTM) $78.01B
Div Yield 0.71%
ROE (TTM) -124.0%
Debt/Equity (MRQ) -6.5
52W Range $354–$557

HCA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

About HCA Healthcare, Inc. Common Stock Company overview from Wikipedia

05 · wikidata

HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.

History

Early years

The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was chief executive.

The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.

Growth and merger

The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.

In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.

In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,

to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.

Columbia Hospital Corporation

In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.

In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.

Recent history

On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.

In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.

In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.

In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.

In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.

In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.

In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.

In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.

Facilities

United States

As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.

Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.

In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.

In 2019 they purchased Mission Health System which operates hospitals in North Carolina.

In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.

In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.

United Kingdom

HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:

It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.

The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.

The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.

Significant areas of operation

Medical education

In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.

Controversies

Medicare billing practices lawsuit

In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.

The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.

2005 insider trading suit

In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.

COVID-19 PPE

During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.

Mission Hospital Acquisition Complaints

On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.

On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

sectorHealth Care industryHealth Care employees230,000 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$75.60B
2016-12-31 → 2025-12-31
EPS$28.33
2016-12-31 → 2025-12-31
Free Cash Flow$7.69B
2016-12-31 → 2025-12-31
Net margin8.8%
2018-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend HCA 5Y avg Peer Median Verdict
P/E (TTM) 14.35Y avg ≈13.8 ≈13.8 16.5 Undervalued
P/S (TTM) 1.25Y avg ≈1.2 ≈1.2 1.2 Fair value
P/B (MRQ) -14.05Y avg ≈-39.2 ≈-39.2 · ·
EV / EBITDA 38.75Y avg ≈37.3 ≈37.3 18.9 Overvalued
Price / FCF (TTM) 15.55Y avg ≈14.6 ≈14.6 · ·
Price / Cash Flow (TTM) 8.45Y avg ≈7.9 ≈7.9 9.1 Undervalued
EV / Revenue 1.85Y avg ≈1.8 ≈1.8 · ·
EV / FCF 17.75Y avg ≈21.8 ≈21.8 · ·
PEG Ratio ≈0.7 · · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Dividends Yield, payout ratio, dividend history, 5Y CAGR

13
Dividend Yield0.71%
Payout Ratio10.0%
Annualized Payout≈$3.12Paid quarterly
5Y Div CAGR≈21.9%Per share, split-adjusted
Growth Streak≈5Consecutive years of dividend growth
Ex-dateAmountCurrencyYield
Sep 16, 2026$0.78USD≈0.71%
Jun 16, 2026$0.78USD≈0.76%
Mar 17, 2026$0.78USD≈0.58%
Dec 15, 2025$0.72USD≈0.60%
Sep 16, 2025$0.72USD≈0.71%
Jun 16, 2025$0.72USD≈0.75%
Mar 17, 2025$0.72USD≈0.82%
Dec 13, 2024$0.66USD≈0.84%
Sep 16, 2024$0.66USD≈0.64%
Jun 14, 2024$0.66USD≈0.75%
Mar 14, 2024$0.66USD≈0.76%
Dec 13, 2023$0.60USD≈0.89%
Sep 14, 2023$0.60USD≈0.90%
Jun 15, 2023$0.60USD≈0.81%
Mar 16, 2023$0.60USD≈0.90%
Dec 13, 2022$0.56USD≈0.92%
Sep 15, 2022$0.56USD≈1.0%
Jun 15, 2022$0.56USD≈1.1%
Mar 16, 2022$0.56USD≈0.75%
Dec 13, 2021$0.48USD≈0.90%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 7.9%
Next Report Oct 22, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Jul 23, 2026 $7.62 $7.54 1.0%
March 31, 2026 $7.15 $7.21 -0.85%
Dec. 31, 2025 $8.14 $7.53 8.0%
Sept. 30, 2025 $6.96 $5.77 20.6%
June 30, 2025 $6.83 $6.31 8.2%
March 31, 2025 $6.45 $5.84 10.5%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 12
Metric Trend 2025202420232022202120202019201820172016
Revenue $75.60B$70.60B$64.97B$60.23B$58.75B$51.53B$51.34B$46.68B$43.61B$41.49B
SG&A Expense $548M$421M$353M$307M$337M$416M$370M$344M$340M$343M
Operating Expenses $65.77B$62.08B$57.26B$51.65B$48.92B$46.10B$46.09B$41.34B$39.23B$36.68B
Interest Expense $2.25B$2.06B$1.94B$1.74B$1.57B$1.58B$1.82B$1.75B$1.69B$1.71B
Pretax Income $9.83B$8.52B$7.71B$8.58B$9.83B$5.43B$5.24B$5.33B$4.38B$4.81B
Income Tax $2.05B$1.87B$1.61B$1.75B$2.11B$1.04B$1.10B$946M$1.64B$1.38B
Net Income $6.78B$5.76B$5.24B$5.64B$6.96B$3.75B$3.50B$3.79B$2.22B$2.89B
EPS (Basic) $28.70$22.27$19.25$19.43$21.52$11.10$10.27$10.90$6.12$7.53
EPS (Diluted) $28.33$22.00$18.97$19.15$21.16$10.93$10.07$10.66$5.95$7.30
Shares (Basic) 236,413,000258,603,000272,404,000290,348,000323,315,000338,274,000341,210,000347,297,000362,305,000383,591,000
Shares (Diluted) 239,495,000261,806,000276,412,000294,666,000328,752,000343,605,000348,226,000355,303,000372,221,000395,851,000
EBITDA $3.52B$3.31B$3.08B$2.97B$2.85B$2.72B$2.60B$2.28B$2.13B$1.97B
Balance Sheet 22
Metric Trend 2025202420232022202120202019201820172016
Cash & Equivalents $1.04B$1.93B$935M$908M$1.45B$1.79B$621M$502M$732M$646M
Short-term Investments ·····$116M$147M$47M$54M$49M
Receivables $10.87B$10.75B$9.96B$8.89B$8.10B$7.05B$7.38B$6.79B$6.50B$5.83B
Inventory $1.65B$1.74B$2.02B$2.07B$1.99B$2.02B$1.85B$1.73B$1.57B$1.50B
Other Current Assets $2.22B$1.99B$2.01B$1.78B$2.01B$1.46B$1.35B$1.19B$1.17B$1.11B
Current Assets $15.78B$16.41B$14.93B$13.64B$13.54B$12.33B$11.20B$10.21B$9.98B$9.09B
PP&E (Net) $31.14B$29.41B$27.71B$25.57B$24.06B$23.20B$22.71B$19.76B$17.89B$16.35B
PP&E (Gross) $66.28B$62.51B$58.55B$54.76B$51.35B$49.32B$47.23B$42.97B$40.08B$37.05B
Accum. Depreciation $35.13B$33.10B$30.83B$29.18B$27.29B$26.12B$24.52B$23.21B$22.19B$20.70B
Other Non-current Assets $255M$230M$184M$298M$598M$546M$480M$690M$710M$1.07B
Total Assets $60.72B$59.51B$56.21B$52.44B$50.74B$47.49B$45.06B$39.21B$36.59B$33.76B
Accounts Payable $4.66B$4.28B$4.23B$4.24B$4.11B$3.54B$2.90B$2.58B$2.61B$2.32B
Current Liabilities $16.35B$15.18B$12.65B$9.90B$9.58B$8.70B$7.76B$7.57B$6.16B$5.83B
Capital Leases $1.85B$1.86B$1.90B$1.75B$1.75B$1.67B$1.50B···
Total Liabilities ······$45.62B$42.12B$41.59B$39.39B
Long-term Debt $44.28B$43.03B$39.59B$38.08B$34.58B$31.00B$33.72B$32.82B$33.06B$31.38B
Total Debt $41.60B$43.03B$39.59B$38.08B$34.58B$31.00B$33.72B$32.82B$33.06B$31.38B
Retained Earnings $-5.72B$-2.12B$-1.35B$-2.28B$-532M$777M$-2.35B$-4.57B$-6.53B$-6.97B
AOCI $-305M$-387M$-425M$-490M$-404M$-502M$-460M$-381M$-278M$-338M
Stockholders' Equity $-6.03B$-2.50B$-1.77B$-2.77B$-933M$572M$-2.81B$-4.95B$-6.81B$-7.30B
Liabilities + Equity $60.72B$59.51B$56.21B$52.44B$50.74B$47.49B$45.06B$39.21B$36.59B$33.76B
Shares Outstanding 224,605,100249,981,400265,537,300277,378,300305,476,800339,425,600338,445,600342,895,200350,091,600370,535,900
Cash Flow 17
Metric Trend 2025202420232022202120202019201820172016
D&A $3.52B$3.31B$3.08B$2.97B$2.85B$2.72B$2.60B$2.28B$2.13B$1.97B
Stock-based Comp $401M$360M$262M$341M$440M$362M$347M$268M$270M$251M
Amort. of Intangibles $12M$16M$20M$44M$25M$26M····
Other Non-cash $1.93B$1.08B$850M$-431M$-1.29B$2.40B$1.07B$461M$-3.53B$-2.67B
Operating Cash Flow $12.64B$10.51B$9.43B$8.52B$8.96B$9.23B$7.60B$6.76B$5.43B$5.65B
CapEx $4.94B$4.88B$4.74B$4.39B$3.58B$2.83B$4.16B$3.57B$3.02B$2.76B
Investing Cash Flow $-4.99B$-4.93B$-5.32B$-3.39B$-2.64B$-3.39B$-5.72B$-3.90B$-4.28B$-3.24B
Debt Issued $8.47B$7.50B$3.22B$6.00B$4.34B$2.70B$6.45B$2.00B$1.50B$5.40B
Net Debt Issued $1.08B$5.08B$2.31B$3.17B$475M$-737M$1.13B$296M$749M$925M
Stock Repurchased $10.07B$6.04B$3.81B$7.00B$8.21B$441M$1.03B$1.53B$2.05B$2.75B
Net Stock Activity $-10.07B$-6.04B$-3.81B$-7.00B$-8.21B$-441M$-1.03B$-1.53B$-2.05B$-2.75B
Dividends Paid $679M$690M$661M$653M$624M$153M$550M$487M$0·
Financing Cash Flow $-8.55B$-4.58B$-4.09B$-5.66B$-6.66B$-4.68B$-1.77B$-3.08B$-1.06B$-2.51B
Net Change in Cash $-893M$998M$27M$-543M$-342M$1.17B$119M$-230M$86M$-95M
Taxes Paid $1.74B$1.84B$1.39B$1.18B$2.18B$1.00B$849M$872M$1.21B$1.25B
Free Cash Flow $7.69B$5.64B$4.69B$4.13B$5.38B$6.40B$3.44B$3.19B$2.41B$2.89B
Levered FCF $5.91B$4.03B$3.16B$2.74B$4.15B$5.12B$2.00B$1.74B$1.35B$1.68B
Profitability 5
Metric Trend 2025202420232022202120202019201820172016
Net Margin 9.0%8.2%8.1%9.4%11.8%7.3%6.8%8.1%··
Pretax Margin 13.0%12.1%11.9%14.2%16.7%10.5%10.2%11.4%··
EBITDA Margin 4.7%4.7%4.7%4.9%4.9%5.3%5.1%4.9%··
ROA 11.3%10.0%9.7%10.9%14.2%8.1%8.3%10.0%6.3%8.7%
ROE -159.1%-269.6%-230.9%-305.0%-3853.7%-335.8%-90.4%-64.4%-31.4%-38.8%
Liquidity & Solvency 4
Metric Trend 2025202420232022202120202019201820172016
Current Ratio 1.01.11.21.41.41.41.41.31.61.6
Quick Ratio 0.70.80.91.01.01.01.11.01.21.1
Debt / Equity -6.9-17.2-22.3-13.8-37.154.2-12.0-6.6-4.9-4.3
LT Debt / Equity -6.9-15.3-21.0-13.6-36.853.8-12.0-6.5-4.8-4.3
Efficiency 2
Metric Trend 2025202420232022202120202019201820172016
Asset Turnover 1.31.21.21.21.21.11.21.2··
Receivables Turnover 7.06.86.97.17.87.17.27.0··
Per Share 6
Metric Trend 2025202420232022202120202019201820172016
Book Value / Share $-26.83$-10.00$-6.68$-9.98$-3.05$1.69$-8.30$-14.44$-19.44$-19.71
Revenue / Share $315.66$269.68$235.04$204.41$178.71$149.98$147.42$131.37··
Cash Flow / Share $52.76$40.16$34.12$28.92$27.25$26.87$21.83$19.03$14.58$14.28
Cash / Share $4.63$7.73$3.52$3.27$4.75$5.28$1.83$1.46$2.09$1.74
Dividend / Share $2.88$2.64$2.40$2.24$1.92$0.43$1.60$1.40··
EPS (TTM) $28.33$22.00$18.97$19.15$21.16$10.93$10.07$10.66$5.95$7.30
Growth Rates 10
Metric Trend 2025202420232022202120202019201820172016
Revenue YoY 7.1%8.7%7.9%2.5%14.0%·····
Revenue CAGR 3Y 7.9%6.3%8.0%·······
Revenue CAGR 5Y 8.0%·········
EPS YoY 28.8%16.0%-0.94%-9.5%93.6%·····
EPS CAGR 3Y 13.9%1.3%20.2%·······
EPS CAGR 5Y 21.0%·········
Net Income YoY 17.8%9.9%-7.1%-18.9%85.3%·····
Net Income CAGR 3Y 6.3%-6.1%11.8%·······
Net Income CAGR 5Y 12.6%·········
Dividends Paid CAGR 5Y 34.7%·········
Valuation (TTM) 17
Metric Trend 2025202420232022202120202019201820172016
Revenue TTM $75.60B$70.60B$64.97B$60.23B$58.75B$51.53B$51.34B$46.68B$43.61B$41.49B
Net Income TTM $6.78B$5.76B$5.24B$5.64B$6.96B$3.75B$3.50B$3.79B$2.22B$2.89B
Market Cap $104.86B$75.03B$71.88B$66.56B$78.48B$55.82B$50.03B$42.67B$30.75B$27.43B
Enterprise Value $145.42B$116.13B$110.53B$103.74B$111.61B$84.92B$82.98B$74.95B$63.02B$58.11B
P/E 16.513.614.312.512.115.014.711.714.810.1
P/S 1.41.11.11.11.31.11.00.90.70.7
P/B -17.4-30.0-40.5-24.1-84.197.6-17.8-8.6-4.5-3.8
P / Tangible Book ·····97.6····
P / Cash Flow 8.37.17.67.88.86.06.66.35.74.9
P / FCF 13.613.315.316.114.68.714.513.412.89.5
EV / EBITDA 41.335.135.934.939.131.232.032.929.629.6
EV / FCF 18.920.623.625.120.713.324.123.526.120.1
EV / Revenue 1.91.61.71.71.91.61.61.61.41.4
Dividend Yield 0.65%0.92%0.92%0.98%0.80%0.27%1.1%1.1%0.00%·
Earnings Yield 6.1%7.3%7.0%8.0%8.2%6.7%6.8%8.6%6.8%9.9%
Payout Ratio 10.0%12.0%12.6%11.6%9.0%4.1%15.7%12.9%··
Annual Payout $679M$690M$661M$653M$624M$153M$550M$487M$0·

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $75.60B $70.60B $64.97B $60.23B $58.75B
Net Income $6.78B $5.76B $5.24B $5.64B $6.96B
Diluted EPS $28.33 $22.00 $18.97 $19.15 $21.16

Institutional owners (13F) 1,473 filers · $57.3B total · As of Sept. 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 1,473
Value held $57.3B
New positions 121
Exited positions 176
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
121 (-64 vs prior Q) 176 (+72 vs prior Q) 458 (-25 vs prior Q) 581 (+4 vs prior Q) -627K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
VANGUARD GROUP INC $6,870,392,526 14,716,173 12.00% Shares
BlackRock, Inc. $5,069,973,824 13,003,600 8.85% Shares
VANGUARD CAPITAL MANAGEMENT LLC $3,954,150,533 10,141,708 6.91% Shares
Sanders Capital, LLC $3,442,060,818 8,828,287 6.01% Shares
STATE STREET CORP $2,912,102,056 7,469,035 5.09% Shares
WELLINGTON MANAGEMENT GROUP LLP $1,835,396,649 4,707,473 3.21% Shares
GEODE CAPITAL MANAGEMENT, LLC $1,423,654,808 3,668,008 2.49% Shares
First Eagle Investment Management, LLC $1,284,907,912 3,295,565 2.24% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $1,057,704,509 2,712,828 1.85% Shares
MORGAN STANLEY $1,008,556,857 2,586,771 1.76% Shares
GOLDMAN SACHS GROUP INC $960,811,481 2,464,314 1.68% Shares
JPMORGAN CHASE & CO $896,800,955 2,285,832 1.57% Shares
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $861,456,107 2,209,485 1.50% Shares
NORGES BANK $836,457,140 2,145,367 1.46% Shares
Capital World Investors $770,864,224 1,977,121 1.35% Shares
Capital International Investors $747,403,041 1,916,947 1.31% Shares
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $709,859,997 1,500,000 1.24% Shares
NORTHERN TRUST CORP $666,150,458 1,708,560 1.16% Shares
FMR LLC $636,503,475 1,632,520 1.11% Shares
Invesco Ltd. $596,390,232 1,529,637 1.04% Shares
NORDEA INVESTMENT MANAGEMENT AB $553,702,529 1,429,943 0.97% Shares
BARCLAYS PLC $514,349,127 1,319,216 0.90% Shares
JANUS HENDERSON GROUP PLC $481,486,890 1,017,441 0.84% Shares
Crake Asset Management LLP $449,072,183 1,151,792 0.78% Shares
Metropolis Capital Ltd $430,915,307 910,564 0.75% Shares
Darsana Capital Partners LP $428,879,000 1,100,000 0.75% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $414,565,358 1,063,288 0.72% Shares
Legal & General Group Plc $410,992,402 1,054,124 0.72% Shares
FRANKLIN RESOURCES INC $399,958,688 1,025,824 0.70% Shares
Life Cycle Investment Partners Ltd $355,737,196 912,404 0.62% Shares
Bank of New York Mellon Corp $350,359,895 898,612 0.61% Shares
VANGUARD FIDUCIARY TRUST CO $339,685,814 871,235 0.59% Shares
ROYAL BANK OF CANADA $320,194,000 821,241 0.56% Shares
LYRICAL ASSET MANAGEMENT LP $255,015,742 654,071 0.45% Shares
BANK OF AMERICA CORP /DE/ $238,456,934 611,601 0.42% Shares
SCHRODER INVESTMENT MANAGEMENT GROUP $237,236,367 608,470 0.41% Shares
ROYAL LONDON ASSET MANAGEMENT LTD $235,649,908 604,401 0.41% Shares
PRINCIPAL FINANCIAL GROUP INC $234,827,401 602,290 0.41% Shares
UBS Group AG $230,953,291 592,355 0.40% Shares
National Pension Service $230,650,346 591,578 0.40% Shares
Russell Investments Group, Ltd. $206,832,565 530,340 0.36% Shares
Nuveen, LLC $199,595,109 511,927 0.35% Shares
Gobi Capital LLC $195,742,325 502,045 0.34% Shares
Cryder Capital Partners LLP $194,561,738 499,017 0.34% Shares
Allianz Asset Management GmbH $181,127,299 464,560 0.32% Shares
DEUTSCHE BANK AG\ $175,985,429 451,372 0.31% Shares
Swiss National Bank $172,097,446 441,400 0.30% Shares
DIMENSIONAL FUND ADVISORS LP $172,079,393 441,313 0.30% Shares
AustralianSuper Pty Ltd $159,635,782 409,438 0.28% Shares
HSBC HOLDINGS PLC $158,555,065 406,750 0.28% Shares

Show all 1,473 institutional owners →

Activists & 5%+ owners 4 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan Feb. 10, 2026 31.60% Initial filing · SEC
Nov. 22, 2006 · Initial filing · SEC
Merrill Lynch Bank USA Sept. 11, 2006 · Initial filing · SEC
Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC Aug. 4, 2006 · Initial filing · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 92 insiders · 54 officers · 31 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Samuel N Hazen CEO Feb. 10, 2026 F 64,842 0 7 $-21,483,290
O'Boyle Michael P President & CEO - Parallon Feb. 26, 2013 A 21,429 0 0 $0
Mike A Marks EVP and CFO May 7, 2026 G 46,576 0 0 $0
Bill B Rutherford CFO and EVP Feb. 16, 2024 F 22,251 0 0 $0
Russell K Harms CFO - Central Group Nov. 17, 2006 D 0 0 0 $0
Robert Samuel Hankins JR CFO-Outpatient Services Group Nov. 17, 2006 D 0 0 0 $0
Richard J Shallcross CFO - Western Group Nov. 17, 2006 D 0 0 0 $0
Jeffrey T Crudele CFO-Eastern Division July 1, 2005 F 13,865 0 0 $0
Erol R Akdamar Group President Nov. 12, 2024 M 6,843 0 0 $0
Timothy M Mcmanus Group President July 31, 2024 M 27,008 0 0 $0
Richard A Hammett Group President Feb. 16, 2024 F 17,936 0 0 $0
Charles J Hall Group President Nov. 11, 2022 M 202,443 0 0 $0
Bruce A Moore JR Group President - Service Line Nov. 11, 2022 S 30,807 0 0 $0
Paul W Rutledge Group President Dec. 31, 2012 A 335,657 0 0 $0
Beverly B Wallace President - Parallon Nov. 2, 2011 M 144,714 0 0 $0
Charles Robert Evans President - Eastern Group July 26, 2006 A 62,173 0 0 $0
Marilyn B Tavenner President-Outpatient Svcs Grp Oct. 27, 2005 A 26,154 0 0 $0
Greg Roth President-Ambulatory Surgery Oct. 31, 2004 D 9,029 0 0 $0
Jay Grinney President-Eastern Group May 7, 2004 D 24,177 0 0 $0
Jon M Foster EVP and COO Feb. 10, 2026 F 23,062 0 0 $0
Michael R Mcalevey EVP & Chief Legal & Admin Off. Aug. 26, 2026 J 0 0 2 $-2,747,520
Jennifer Berres SVP & Chief Human Res. Officer Feb. 11, 2026 S 11,993 0 2 $-4,126,932
Christopher F. Wyatt SVP & Controller Feb. 11, 2026 S 44,379 0 1 $-2,020,000
Erica Rossitto SVP & Chief Nurse Executive Feb. 10, 2026 F 10,407 0 0 $0
Michael S. Cuffe EVP and Chief Clinical Officer Feb. 10, 2026 F 32,080 0 1 $-747,135
Sammie S Mosier SVP & Chief Nurse Executive Feb. 13, 2025 F 11,113 0 0 $0
Kathleen M Whalen SVP & Chief Ethics Officer Nov. 14, 2024 S 9,454 0 0 $0
Phillip G Billington SVP-Internal Audit Services Nov. 12, 2024 M 52,702 0 0 $0
Joseph A Sowell III SVP; Chief Development Officer Aug. 5, 2024 G 18,526 0 0 $0
Deborah M Reiner SVP - Mktg. & Communications July 29, 2024 S 3,510 0 0 $0
Kathryn A. Torres SVP-Payer Contracting & Align. July 25, 2024 S 17,755 0 0 $0
Jeffrey E. Cohen SVP-Government Relations May 9, 2024 S 5,185 0 0 $0
Chad J Wasserman SVP and CIO March 18, 2024 M 1,576 0 0 $0
Martin P. Paslick SVP and CIO April 12, 2023 M 24,643 0 0 $0
Jane D. Englebright SVP and Chief Nursing Officer Nov. 9, 2021 S 0 0 0 $0
Robert A Waterman SVP & General Counsel May 5, 2021 S 50,062 0 0 $0
William J Morrow SVP - Finance and Treasurer Feb. 18, 2021 F 5,578 0 0 $0
Sandra L. Morgan SVP-Provider Relations Feb. 18, 2021 F 10,122 0 0 $0
Victor L Campbell SVP-Government Affairs May 1, 2019 A 194,145 0 0 $0
John M Steele SVP & Chief Human Res. Officer Feb. 25, 2019 M 84,157 0 0 $0
Milton R Johnson Chairman Feb. 25, 2019 M 881,823 0 0 $0
Ravi S. Chari SVP-Clinical Excellence Feb. 25, 2018 M 7,003 0 0 $0
Alan R Yuspeh SVP & Chief Ethics Officer Feb. 25, 2018 M 35,546 0 0 $0
Joseph N Steakley SVP-Internal Audit Services Feb. 25, 2018 M 65,199 0 0 $0
Jana Joustra Davis SVP - Mktg. & Corp. Affairs May 23, 2017 M 26,378 0 0 $0
David Gwin Anderson SVP - Finance Nov. 7, 2016 M 110,167 0 0 $0
Donald W Stinnett SVP & Controller Feb. 25, 2016 A 51,965 0 0 $0
Noel B Williams SVP and CIO May 16, 2012 M 299,030 0 0 $0
Jack O Bovender JR Chairman Oct. 6, 2009 A 188,340 0 0 $0
Carl V George SVP - Development Feb. 27, 2009 M 13,092 0 0 $0
Patricia T Lindler SVP - Government Programs Nov. 17, 2006 D 0 0 0 $0
Rosalyn S Elton SVP-Operations Finance Nov. 17, 2006 D 0 0 0 $0
Frank M Houser MD SVP-Quality & Medical Director July 26, 2006 A 46,145 0 0 $0
James A Fitzgerald JR SVP-Supply Chain Operations Jan. 29, 2006 F 20,674 0 0 $0
Andrea B Smith Director April 28, 2026 A 4,666 0 0 $0
William R Frist Director April 28, 2026 A 13,740 0 0 $0
Wayne Joseph Riley Director April 28, 2026 A 15,029 0 0 $0
Hugh F Johnston Director April 28, 2026 A 4,475 0 0 $0
Thomas F Frist III Director April 28, 2026 A 15,858 0 0 $0
Michael W Michelson Director April 28, 2026 A 12,576 0 0 $0
Nancy Ann Deparle Director April 28, 2026 A 21,910 0 0 $0
John Chidsey Director April 28, 2026 A 1,305 0 0 $0
Robert J Dennis Director April 29, 2025 A 26,601 0 0 $0
Meg Crofton Director April 29, 2024 A 6,331 0 0 $0
Charles O Holliday JR Director April 25, 2022 A 18,955 0 0 $0
Geoffrey G Meyers Director May 1, 2019 A 39,153 0 0 $0
John W Rowe Director May 1, 2019 A 30,388 0 0 $0
Ann H Lamont Director May 2, 2018 A 17,661 0 0 $0
Jay O Light Director May 3, 2017 A 30,953 0 0 $0
Stephen G Pagliuca Director Dec. 5, 2014 D 7,612,921 0 0 $0
Christopher R Gordon Director Nov. 1, 2013 D 30,003,156 0 0 $0
John Connaughton Director Nov. 1, 2013 D 30,003,156 0 0 $0
John H Mcarthur Director Nov. 17, 2006 D 0 0 0 $0
Kent C Nelson Director Nov. 17, 2006 D 0 0 0 $0
Magdalena Averhoff MD Director Nov. 17, 2006 D 0 0 0 $0
Glenda A Hatchett Director Nov. 17, 2006 D 0 0 0 $0
Frederick W Gluck Director Nov. 17, 2006 D 0 0 0 $0
Harold T Shapiro Director Nov. 17, 2006 D 0 0 0 $0
Michael C Armstrong Director Nov. 17, 2006 D 0 0 0 $0
Martin Feldstein Director Nov. 17, 2006 D 0 0 0 $0
Michael T Long Director Nov. 17, 2006 D 0 0 0 $0
ROYAL FRANK S Director Nov. 17, 2006 D 0 0 0 $0
Patricia F Elcan 10% owner Feb. 6, 2026 J 36,557,141 0 0 $0
Frisco Holding II 10% owner Feb. 6, 2026 J 36,557,141 0 0 $0
HERCULES HOLDING II, LLC 10% owner Feb. 6, 2026 J 32,282,889 0 0 $0
Thomas F Frist JR 10% owner Feb. 6, 2026 J 36,557,141 0 0 $0
Patricia C Frist 10% owner Feb. 20, 2018 G 0 0 0 $0
KKR PEI GP LTD 10% owner April 1, 2014 J 0 0 0 $0
Jonathan B Perlin · Aug. 2, 2021 S 44,348 0 0 $0
Juan Vallarino · May 9, 2016 M 61,036 0 0 $0
Richard M Bracken · Dec. 31, 2014 F 82,499 0 0 $0
BANK OF AMERICA CORP /DE/ · Nov. 6, 2012 S 2,652,364 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 141 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
BUL · Pacer Funds Trust 5.07% 16,545 NS July 31, 2026 N-PORT
IHF · iShares Trust 4.75% 147,977 SH Sept. 11, 2026 Daily
STNC · Hennessy Funds Trust 3.17% 7,315 NS July 31, 2026 N-PORT
PKW · Invesco Exchange-Traded Fund Trust 2.45% 97,235 SH Oct. 2, 2026 Daily
COWZ · Pacer Funds Trust 2.07% 960,711 NS July 31, 2026 N-PORT
WLTG · ETF Opportunities Trust 2.06% 3,942 NS July 31, 2026 N-PORT
RSPH · Invesco Exchange-Traded Fund Trust 1.66% 34,083 SH Oct. 2, 2026 Daily
RPG · Invesco Exchange-Traded Fund Trust 1.27% 58,580 SH Oct. 2, 2026 Daily
FLAG · Global X Funds 1.14% 48 NS July 31, 2026 N-PORT
FCPI · FIDELITY COVINGTON TRUST 1.03% 6,909 NS July 31, 2026 N-PORT
IYH · iShares Trust 1.01% 87,417 SH Sept. 11, 2026 Daily
SRHQ · Elevation Series Trust 0.94% 4,938 NS July 31, 2026 N-PORT
NEAR · iShares U.S. ETF Trust 0.92% 48,109,000 SH Sept. 11, 2026 Daily
FHLC · FIDELITY COVINGTON TRUST 0.91% 74,445 NS July 31, 2026 N-PORT
VHT · VANGUARD WORLD FUND 0.90% 470,451 SH Aug. 19, 2026 Daily
FXH · First Trust Exchange-Traded AlphaDE… 0.87% 22,725 NS July 31, 2026 N-PORT
DIVB · iShares Trust 0.87% 42,100 SH Sept. 11, 2026 Daily
NFRA · FlexShares Trust 0.84% 62,628 NS July 31, 2026 N-PORT
IXJ · iShares Trust 0.83% 81,708 SH Sept. 11, 2026 Daily
SPVM · Invesco Exchange-Traded Fund Trust 0.80% 2,483 SH Oct. 2, 2026 Daily
QUVU · Hartford Funds Exchange-Traded Trust 0.79% 3,522 NS July 31, 2026 N-PORT
BSCT · Invesco Exchange-Traded Self-Indexe… 0.78% 23,458,000 Oct. 2, 2026 Daily
BSCS · Invesco Exchange-Traded Self-Indexe… 0.74% 25,897,000 Oct. 1, 2026 Daily
CURE · Direxion Shares ETF Trust 0.72% 3,056 NS July 31, 2026 N-PORT
VFMF · VANGUARD WELLINGTON FUND 0.67% 12,075 SH Aug. 19, 2026 Daily
LGDX · Tidal Trust III 0.66% 2,345 NS July 31, 2026 N-PORT
VFVA · VANGUARD WELLINGTON FUND 0.55% 11,876 SH Aug. 19, 2026 Daily
BSCR · Invesco Exchange-Traded Self-Indexe… 0.50% 23,126,000 Oct. 2, 2026 Daily
LSVD · ADVISORS' INNER CIRCLE FUND 0.46% 7,404 NS July 31, 2026 N-PORT
WLDR · Two Roads Shared Trust 0.43% 964 NS July 31, 2026 N-PORT
ROUS · Lattice Strategies Trust 0.42% 7,289 NS July 31, 2026 N-PORT
RWL · Invesco Exchange-Traded Fund Trust … 0.40% 92,161 SH Oct. 2, 2026 Daily
QLC · FlexShares Trust 0.39% 9,856 NS July 31, 2026 N-PORT
XOEF · iShares Trust 0.37% 194 SH Sept. 11, 2026 Daily
GSY · Invesco Actively Managed Exchange-T… 0.36% 14,000,000 Oct. 2, 2026 Daily
UPSD · ETF Series Solutions 0.33% 972 NS July 31, 2026 N-PORT
BSCU · Invesco Exchange-Traded Self-Indexe… 0.33% 9,324,000 Oct. 2, 2026 Daily
MGV · VANGUARD WORLD FUND 0.29% 97,604 SH Aug. 19, 2026 Daily
PFIG · Invesco Exchange-Traded Fund Trust … 0.28% 390,000 Oct. 2, 2026 Daily
JPUS · J.P. Morgan Exchange-Traded Fund Tr… 0.28% 3,186 NS July 31, 2026 N-PORT
USXF · iShares Trust 0.26% 9,226 SH Sept. 11, 2026 Daily
IUS · Invesco Exchange-Traded Self-Indexe… 0.26% 5,813 SH Oct. 2, 2026 Daily
IWX · iShares Trust 0.23% 21,535 SH Sept. 11, 2026 Daily
VTV · VANGUARD INDEX FUNDS 0.23% 1,475,731 SH Aug. 19, 2026 Daily
JMOM · J.P. Morgan Exchange-Traded Fund Tr… 0.23% 14,235 NS July 31, 2026 N-PORT
MPLY · Strategy Shares 0.22% 87 NS July 31, 2026 N-PORT
EUSA · iShares, Inc. 0.21% 9,589 SH Sept. 11, 2026 Daily
RSP · Invesco Exchange-Traded Fund Trust 0.21% 462,724 SH Oct. 2, 2026 Daily
FTC · First Trust Exchange-Traded AlphaDE… 0.20% 6,420 NS July 31, 2026 N-PORT
SIZE · iShares Trust 0.19% 1,920 SH Sept. 11, 2026 Daily
DYNF · BlackRock ETF Trust 0.19% 183,934 SH Sept. 11, 2026 Daily
VMAX · Lattice Strategies Trust 0.19% 228 NS July 31, 2026 N-PORT
DSI · iShares Trust 0.19% 23,734 SH Sept. 11, 2026 Daily
ILCV · iShares Trust 0.18% 5,870 SH Sept. 10, 2026 Daily
IVW · iShares Trust 0.18% 331,185 SH Sept. 11, 2026 Daily
IUSG · iShares Trust 0.17% 136,713 SH Sept. 11, 2026 Daily
VOOG · VANGUARD ADMIRAL FUNDS 0.17% 115,334 SH Aug. 19, 2026 Daily
IWD · iShares Trust 0.17% 332,035 SH Sept. 11, 2026 Daily
VONV · VANGUARD SCOTTSDALE FUNDS 0.16% 90,157 SH Aug. 19, 2026 Daily
OMFL · Invesco Exchange-Traded Self-Indexe… 0.16% 17,773 SH Oct. 2, 2026 Daily
USMV · iShares Trust 0.16% 89,855 SH Sept. 11, 2026 Daily
ACWV · iShares, Inc. 0.15% 11,903 SH Sept. 11, 2026 Daily
EGLE · Global X Funds 0.15% 8 NS July 31, 2026 N-PORT
GLBL · Pacer Funds Trust 0.15% 4 NS July 31, 2026 N-PORT
PRF · Invesco Exchange-Traded Fund Trust 0.14% 33,327 SH Oct. 2, 2026 Daily
VOXP · Advisors Series Trust 0.13% 18 NS July 31, 2026 N-PORT
VRIG · Invesco Actively Managed Exchange-T… 0.12% 2,250,000 Oct. 1, 2026 Daily
TOPC · iShares Trust 0.12% 95 SH Sept. 11, 2026 Daily
DGRO · iShares Trust 0.12% 120,741 SH Sept. 11, 2026 Daily
XVV · iShares Trust 0.11% 1,790 SH Sept. 11, 2026 Daily
QVML · Invesco Exchange-Traded Fund Trust … 0.11% 4,410 SH Oct. 2, 2026 Daily
IWL · iShares Trust 0.11% 5,786 SH Sept. 11, 2026 Daily
MGC · VANGUARD WORLD FUND 0.11% 31,176 SH Aug. 19, 2026 Daily
ACIO · ETF Series Solutions 0.11% 6,205 NS July 31, 2026 N-PORT
EVUS · iShares Trust 0.10% 934 SH Sept. 11, 2026 Daily
ADME · ETF Series Solutions 0.10% 751 NS July 31, 2026 N-PORT
XRMI · Global X Funds 0.10% 126 NS July 31, 2026 N-PORT
XCLR · Global X Funds 0.10% 9 NS July 31, 2026 N-PORT
XYLD · Global X Funds 0.10% 8,148 NS July 31, 2026 N-PORT
XTR · Global X Funds 0.10% 12 NS July 31, 2026 N-PORT
BKLC · BNY Mellon ETF Trust 0.10% 13,621 NS July 31, 2026 N-PORT
VV · VANGUARD INDEX FUNDS 0.10% 181,364 SH Aug. 19, 2026 Daily
ESGV · VANGUARD WORLD FUND 0.10% 33,758 SH Aug. 19, 2026 Daily
IVV · iShares Trust 0.10% 1,957,485 SH Sept. 11, 2026 Daily
PBUS · Invesco Exchange-Traded Fund Trust … 0.10% 26,839 SH Oct. 2, 2026 Daily
PTLC · Pacer Funds Trust 0.10% 7,919 NS July 31, 2026 N-PORT
FAD · First Trust Exchange-Traded AlphaDE… 0.10% 1,395 NS July 31, 2026 N-PORT
PBP · Invesco Exchange-Traded Fund Trust 0.10% 877 SH Oct. 2, 2026 Daily
ILCB · iShares Trust 0.10% 2,915 SH Sept. 11, 2026 Daily
EQAL · Invesco Exchange-Traded Fund Trust … 0.10% 1,794 SH Oct. 2, 2026 Daily
BBUS · J.P. Morgan Exchange-Traded Fund Tr… 0.09% 20,766 NS July 31, 2026 N-PORT
IYY · iShares Trust 0.09% 6,693 SH Sept. 11, 2026 Daily
VOTE · TCW ETF Trust 0.09% 2,545 NS July 31, 2026 N-PORT
FEX · First Trust Exchange-Traded AlphaDE… 0.09% 3,614 NS July 31, 2026 N-PORT
XYLG · Global X Funds 0.09% 147 NS July 31, 2026 N-PORT
DFUS · Dimensional ETF Trust 0.09% 46,791 NS July 31, 2026 N-PORT
IWB · iShares Trust 0.09% 103,721 SH Sept. 11, 2026 Daily
VOO · VANGUARD INDEX FUNDS 0.09% 4,034,357 SH Aug. 19, 2026 Daily
TOV · EA Series Trust 0.09% 607 NS July 31, 2026 N-PORT
SPUU · Direxion Shares ETF Trust 0.09% 586 NS July 31, 2026 N-PORT
ITOT · iShares Trust 0.09% 202,387 SH Sept. 11, 2026 Daily
ACVF · ETF Opportunities Trust 0.09% 337 NS July 31, 2026 N-PORT
GTOS · Invesco Actively Managed Exchange-T… 0.09% 104,000 Oct. 2, 2026 Daily
QDPL · Pacer Funds Trust 0.09% 3,708 NS July 31, 2026 N-PORT
IWV · iShares Trust 0.09% 41,034 SH Sept. 11, 2026 Daily
DFAU · Dimensional ETF Trust 0.08% 25,516 NS July 31, 2026 N-PORT
CRBN · iShares Trust 0.08% 2,269 SH Sept. 11, 2026 Daily
TOK · iShares Trust 0.08% 451 SH Sept. 11, 2026 Daily
VTI · VANGUARD INDEX FUNDS 0.08% 4,930,930 SH Aug. 19, 2026 Daily
VONE · VANGUARD SCOTTSDALE FUNDS 0.08% 24,633 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.08% 12,577 SH Aug. 19, 2026 Daily
PHDG · Invesco Actively Managed Exchange-T… 0.08% 116 SH Oct. 2, 2026 Daily
HCMT · Direxion Shares ETF Trust 0.08% 1,081 NS July 31, 2026 N-PORT
TILT · FlexShares Trust 0.08% 4,108 NS July 31, 2026 N-PORT
SPXL · Direxion Shares ETF Trust 0.07% 12,141 NS July 31, 2026 N-PORT
URTH · iShares, Inc. 0.07% 14,079 SH Sept. 11, 2026 Daily
ACWI · iShares Trust 0.06% 50,294 SH Sept. 11, 2026 Daily
HDUS · Lattice Strategies Trust 0.05% 275 NS July 31, 2026 N-PORT
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0.05% 125,729 SH Aug. 19, 2026 Daily
DCOR · Dimensional ETF Trust 0.05% 3,816 NS July 31, 2026 N-PORT
GLOF · iShares Trust 0.04% 202 SH Sept. 11, 2026 Daily
DUHP · Dimensional ETF Trust 0.04% 10,761 NS July 31, 2026 N-PORT
DFAC · Dimensional ETF Trust 0.02% 28,662 NS July 31, 2026 N-PORT
DFSU · Dimensional ETF Trust 0.02% 1,127 NS July 31, 2026 N-PORT
DXUV · Dimensional ETF Trust 0.01% 99 NS July 31, 2026 N-PORT
GTO · Invesco Actively Managed Exchange-T… 0.00% 42,000 Sept. 30, 2026 Daily
CBLS · Elevation Series Trust -1.12% -1,546 NS July 31, 2026 N-PORT
BIV · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
BLV · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
BSV · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
BND · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
VUSB · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
VCRB · VANGUARD MALVERN FUNDS · · July 15, 2026 Daily
VPLS · VANGUARD MALVERN FUNDS · · July 15, 2026 Daily
VSDB · VANGUARD MALVERN FUNDS · · July 15, 2026 Daily
VCSH · VANGUARD SCOTTSDALE FUNDS · · July 15, 2026 Daily
VCIT · VANGUARD SCOTTSDALE FUNDS · · July 15, 2026 Daily
VCLT · VANGUARD SCOTTSDALE FUNDS · · July 15, 2026 Daily
VTC · VANGUARD SCOTTSDALE FUNDS · · July 30, 2026 Daily
BNDW · VANGUARD SCOTTSDALE FUNDS · · July 30, 2026 Daily
VCEB · VANGUARD WORLD FUND · · July 30, 2026 Daily

HCA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 30 analysts BUY
Median target $450.00 +5.5%
6 20.0% Strong Buy
11 36.7% Buy
12 40.0% Hold
1 3.3% Sell
0 0.0% Strong Sell

12-Month Price Target

22 analysts · 2026-09-28

Mean target $454.23 +6.5%

Now Current price $426.69
Low$380.00 Mean$454.23 High$579.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
HCA $104.86B 16.5 7.1% 9.0% -159.1% ·
THC $17.28B 12.8 3.1% 11.1% 56.4% ·
EHC $10.61B 19.2 10.5% 9.5% 25.1% ·
UHS · 9.4 9.7% 8.6% 21.4% ·
ENSG $10.12B 29.8 18.7% 6.8% 16.9% ·
PACS $6.01B 31.5 29.3% 3.6% 23.1% ·
CON $2.53B 15.1 13.9% 7.7% 49.8% ·
BKD $2.57B -9.6 2.2% -8.2% -313.2% 26.2%
ACHC $1.28B -1.2 5.0% -33.3% -43.9% ·
SNDA $612M -7.7 25.2% -18.6% -197.2% ·

Latest News Recent headlines mentioning this company

23

Trading Signals Recent buy/sell signals with entry price and risk/reward ratio

25

No open signal right now — no card is filled, and that's honest.

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Jul 28, 2026